Personalized Cancer Vaccine

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

Personalized Cancer Vaccine Publisher

Keshavarzfathi M^{1, 2, 3} ; Rezaei N^{3, 4, 5}

Source: Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives Published:2019

Abstract

Personalized medicine is going ahead toward clinical utilization. Due to the recent advances in the “omic” technologies, including genomic studies, the use of individualized approaches has progressed in various diseases including cancer. Individualization has also entered into the field of cancer immunotherapy. Seeking for and selecting the immunogenic neoantigens, which are personalized and unique tumor antigens caused by somatic mutations, is of interest to design specific immunotherapies including vaccines. Recent achievements have been yielded in the clinical trials evaluating synthetic long peptide and poly-neo-epitope RNA vaccines for improvement of disease-free survival in patients at high risk of melanoma recurrence. Hereby, we will review the application of personalized medicine and the related clinical trials in the field of immunotherapy with cancer vaccines. © 2019 Nima Rezaei and Mahsa Keshavarz-Fathi Published by Elsevier Ltd. All rights reserved.

Related Docs

View other Related Docs

1. Personalized Cancer Vaccine, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)

2. Concluding Remarks and Future Perspectives on Therapeutic Cancer Vaccines, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)

3. Concluding Remarks and Future Perspectives on Therapeutic Cancer Vaccines, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (12)

Mohammad Hossein Modarressi (2)

Other Related Docs

4. Development of Neoantigens: From Identification in Cancer Cells to Application in Cancer Vaccines, Expert Review of Vaccines (2022)

5. Candidate Cancers for Vaccination, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)

6. Dna Vaccines As Promising Immuno-Therapeutics Against Cancer: A New Insight, Frontiers in Immunology (2024)

7. Candidate Cancers for Vaccination, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)

8. Mrna Cancer Vaccines From Bench to Bedside: A New Era in Cancer Immunotherapy, Biomarker Research (2024)

9. Tumor Antigen Identification for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)

10. Genetically Modified Immune Cells Targeting Tumor Antigens, Pharmacology and Therapeutics (2020)

11. Immunogenicity of Neoantigens: From Car-T Cell to Various Vaccines, International Journal of Pharmaceutics (2025)

12. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)

13. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)

14. Tumor Antigens, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)

15. Tumor Antigens, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)

16. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools, ACS Pharmacology and Translational Science (2023)

17. Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)

18. Obstacles in the Development of Therapeutic Cancer Vaccines, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)

19. Peptide and Protein Vaccines for Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)

20. Vaccination and Personalized Cancer Vaccines Focusing on Common Cancers in Women: A Narrative Review, Pathology, research and practice (2025)

Style	Citing Format
MLA	Keshavarzfathi M, Rezaei N. "Personalized Cancer Vaccine." Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives, vol. , no. , 2019, pp. 81-89.
APA	Keshavarzfathi M, Rezaei N (2019). Personalized Cancer Vaccine. Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives, (), 81-89.
Chicago	Keshavarzfathi M, Rezaei N. "Personalized Cancer Vaccine." Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives , no. (2019): 81-89.
Harvard	Keshavarzfathi M, Rezaei N (2019) 'Personalized Cancer Vaccine', Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives, (), pp. 81-89.
Vancouver	Keshavarzfathi M, Rezaei N. Personalized Cancer Vaccine. Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives. 2019;():81-89.
BibTex	@article{ author = {Keshavarzfathi M and Rezaei N}, title = {Personalized Cancer Vaccine}, journal = {Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives}, volume = {}, number = {}, pages = {81-89}, year = {2019} }
RIS	TY - JOUR AU - Keshavarzfathi M AU - Rezaei N TI - Personalized Cancer Vaccine JO - Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives VL - IS - SP - 81 EP - 89 PY - 2019 ER -

Science Communicator Platform

Authors

Abstract